



Contact:
Bill Enright
President & CEO
Phone: 240-654-1450
Email: enright@vaxin.com

FOR IMMEDIATE RELEASE

**VAXIN ANNOUNCES THE APPOINTMENT OF M. SCOT ROBERTS TO
CHIEF SCIENTIFIC OFFICER**

Gaithersburg, MD – December 3, 2012 – Vaxin Inc., a clinical stage vaccine development company today announced that M. Scot Roberts, PhD has accepted the position as its Chief Scientific Officer.

“We are excited to have someone with Scot’s background and experience in virology, immunology and biologics development,” said Bill Enright, Vaxin’s CEO. “His prior industry and product development experiences will play an important role in continuing to transition the company from a research focused company to a product development focused company. Scot brings a very strong technical background as well as solid knowledge in the business of science. The combination of this background, together with his leadership skills, are tremendous assets that will be invaluable as we continue to advance our NasoVAX influenza and AdVAV anthrax vaccine candidates and position them for commercial success.”

Dr. Roberts has almost 20 years of senior technical leadership experience, most recently as Chief Scientific Officer at ImQuest BioSciences, Inc. where he was responsible for managing scientific operations as well as business development opportunities for the company. Prior to ImQuest, Dr. Roberts held key positions with Wellstat Biologics Corporation. Dr. Roberts has significant experience in viral research, assay development, upstream process development, animal pharmacology and drug development. Dr. Roberts completed a post-doctoral fellowship at the National Cancer Institute, Laboratory of Molecular Virology and has numerous patents, pending patents and publications in peer-reviewed journals.

Dr. Roberts received his PhD from Johns Hopkins School of Medicine, Department of Pharmacology and Molecular Sciences; and a Master of Science Degree from the Chemistry Department of Illinois State University.

About Vaxin:

Vaxin Inc. is a clinical stage company, developing next generation vaccines to address significant public health and biodefense needs. Vaxin is focused on vaccines designed to protect people against influenza and anthrax infection using proprietary, patented technologies for intranasal delivery, and is also developing unique animal health vaccines including *in ovo* vaccines for preventing influenza outbreaks in poultry populations and a vaccine to sterilize dogs and cats. Vaxin's vaccines are designed to provide a safe, effective, easily administered, rapidly manufactured, and cost-competitive alternative to currently marketed products. Vaxin's intranasally delivered, adenovirus-based vaccines have successfully completed pre-clinical development, Investigational New Drug (IND) review and Phase 1 clinical studies of NasoVAX for seasonal and pre-pandemic influenza indications, demonstrating both proof-of-concept in man and providing an initial safety assessment of the technology platform. The proposed vectored anthrax vaccine product, AdVAV, is identical in route of administration, structure and manufacturing to these influenza candidates with the exception of the encoded antigen (*Bacillus anthracis* PA rather than *influenza virus* HA). It is expected that a nasal anthrax vaccine would greatly boost vaccine coverage against a bioterrorist attack during a crisis, and significantly reduce adverse side effects when compared to those induced by systemically-delivered anthrax vaccines. Vaxin recently received a multi-million dollar BARDA contract to advance this vaccine through Phase 1 clinical studies should the contract option be exercised.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

#